drugset / Trial / NCT05586009

Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients

NCT05586009

Phase 2 Completed 100 enrolled Tanta University
RandomizedParallel-groupSingle-blindPrevention

Summary

The goal of this \[ type of study: intervential study is to compare between different doses of magnesium to prevent cisplatin induced nephrotoxicity.\] In 75 participant population with head and neck cancer recieved cisplatin it aims to answer are: • • optimal doses of magnesium as 3 groups each group take 1gm of magnesium then second group take 2gm of magnesium and finally third group take 3gm of magnesium Researchers will compare \[ 3 groups \] to see if \[ magnesium has effects in prevention cisplatin nephrotoxicity\].

Timeline

Start
2022-10-01
Primary completion
2025-02-27
Completion
2025-03-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Magnesium Sulfate Other / unclassified 1000 mg Intravenous
Comparator Magnesium Sulfate Other / unclassified 2000 mg Intravenous
Comparator Magnesium Sulfate Other / unclassified 3000 mg Intravenous
Comparator Cisplatin Other / unclassified 40 mg/m2 Intravenous

Indications